No description available.

Coacervation is a mild process for developing protein NPs. Bovine serum albumin (BSA) NPs formed via this technique were stabilized using poly-L-Lysine (PLL); short interfering ribonucleic acid (siRNA) was used as a model drug for encapsulation. Specific and non-specific degradation of these coated and uncoated BSA NPs were carried using matrix metalloproteinase-2 (MMP-2) and trypsin, respectively. The particles were characterized with atomic force microscopy, zeta-potential, and photon correlation spectroscopy measurements. There was a significant increase in the zeta potential of BSA NPs upon coating. Trypsin digested the uncoated and coated BSA NPs and resulted in higher BSA release from the particles. However, MMP-2 treatment did not result in higher release of BSA from coated NPs despite the cleavability of coated polymer by MMP-2. This study described a method for obtaining BSA NPs in a controllable size range. Such particles showed degradability in the presence of trypsin and could be promising for targeted drug delivery applications. / Chemical Engineering

Thesis (Ph.D.). / Title from title page of PDF (viewed 2008/01/30). Written for the Dept. of Medicine, Division of Experimental Medicine. Includes bibliographical references.

Matrix metalloproteinase-2 (MMP-2, gelatinase A, type IV collagenase) is a member of a family of zinc-dependent metalloendopeptidases that functions in the degradation of elastin, collagens, and other components of extracellular matrix (ECM). Both secretion and activation of MMP-2 are elevated in human atherosclerotic lesions and abdominal aortic aneurysms (AAA). In this dissertation project, we sought to test the hypothesis that MMP-2 plays a critical role in both atherosclerosis and AAA. We also sought to determine the detailed mechanism. We first examined the atherosclerosis and AngII-induced AAAs development in MMP-2-/- x apolipoprotein (apoE)-/- mice in vivo. It was surprising that MMP-2 deficiency did not reduce the incidence of AngII-induced AAAs or the size of atherosclerosis in apoE-/- mice. However, the cellular and ECM content of atherosclerotic plaques were modified in MMP-2-/- x apoE-/- mice as compared to MMP-2+/+ x apoE-/- control mice. To explain the apparent paradox between this result and the hypothesis, we investigated the morphological characteristics of the aortic wall of MMP-2-/- mice. We detected an enhanced MMP-9 level in the aortic wall of MMP-2-/- x apoE-/- mice compared with MMP-2+/+ x apoE-/- mice. Interestingly, we also observed more branching of the elastin fibers in aortic wall of MMP-2-/- mice as compared with aorta of wild type mice. We also examined the behavior of macrophages from MMP-2-/- mice. Reduced adhesion, migration, and expression of integrin beta 3 were detected in MMP-2 deficient macrophages compared with wild type macrophages. Lastly, we examined whether MMP-2 deficiency in bone marrow-derived cells may influence AAAs and atherosclerosis using bone marrow transplantation technique. There was a significant reduction of both atherosclerosis development and AAAs formation in mice that were reconstituted MMP-2-/- bone marrow cells. In conclusion, the findings in this dissertation suggest that MMP-2 might play an important role in atherosclerosis and aneurysm through influencing inflammatory cell infiltration.

Thesis (M.S.)--University of Tennessee Health Science Center, 2009. / Title from title page screen (viewed on August 5, 2009). Research advisor: David A. Tipton, D.D.S., Ph.D. Document formatted into pages (vi, 39 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 27-38).

Philosophiae Doctor - PhD / Ovarian cancer is called the “Silent Killer” as it is often diagnosed in advanced stages of the disease or misdiagnosed which ends with a poor prognostic outcome for the patient. A high rate of disease relapse, a high incidence-to-mortality ratio as well as acquired multidrug resistance makes it necessary to find alternative diagnostic- and therapeutic tools for ovarian cancer. Nanotechnology describes molecular devices with at least one dimension in the sub- 1μm scale and has been suggested as a possible solution for overcoming challenges in cancer multidrug resistance as well as early diagnosis of the disease. One-pot synthesized gold nanoparticles were used to demonstrate in vitro drug delivery of doxorubicin in a manner which overcame the cytoprotective mechanisms of a multidrug resistant ovarian carcinoma cell line (A2780cis) by inducing apoptosis mediated by caspase-3 within 3h of treatment. The gold nanoparticles were further functionalized with nitrilotriacetic acid and displayed specific interaction with a 6xHis-tagged cancer targeting peptide, chlorotoxin. Proprietary indium based quantum dots were functionalized with the same surface chemistry used for gold nanoparticles and bioconjugated with chlorotoxin. Wide field fluorescence studies showed the peptide-quantum dot construct specifically targeted enhanced green fluorescent tagged matrix metalloproteinase-2 transfected A2780cis cells in a specific manner. The cytoprotective multidrug resistant mechanisms of the ovarian carcinoma was overcome successfully with a single dose of doxorubicin loaded gold nanoparticles and tumour specific targeting was demonstrated using quantum dots with a similar surface chemistry used for the gold nanoparticles.

The Metzincins are a superfamily of zinc-dependent endopeptidases associated with the regulation of the extracellular matrix (ECM). Their members include A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTSs), A Disintegrin and Metalloproteinases (ADAMs), and the matrix metalloproteinases (MMPs). Metzincins exhibit diverse functions associated with both physiological and pathological states that include the proteolytic degradation of the ECM, regulation of various growth factors, cell surface receptors, and chemokines, and mediation of biological functions such as extravasation, survival, and proliferation. In pathological conditions such as cancer associated with chronic inflammation and multiple sclerosis associated with neurodegeneration, dysregulation of Metzincin activities are a hallmark of disease progression and severity. Hence, Metzincins are therapeutic targets for various disease states and research into optimal Metzincin inhibitor design is an ongoing exploit. / Includes bibliography. / Dissertation (Ph.D.)--Florida Atlantic University, 2020. / FAU Electronic Theses and Dissertations Collection

A MMP-2 é uma protease que está envolvida em muitos eventos fisiológicos e patológicos e que compartilha similaridades estruturais com a enzima conversora de angiotensina (ECA), de modo que os inibidores da ECA passaram a ser estudados com relação ao efeito inibitório também sobre a MMP-2. No entanto, este potencial inibitório não foi ainda testado na MMP-2 altamente purificada. Este estudo teve como objetivo investigar o potencial inibitório do captopril sobre a atividade da MMP- 2. Primeiramente, supôs-se que a dissolução do captopril poderia induzir a mudanças no pH de soluções tampão. Em segundo lugar, avaliou-se o efeito direto do captopril sobre a MMP-2 presente no plasma humano e a MMP-2 recombinante humana (rhMMP-2) produzida e purificada de E. coli. As análises de atividade in vitro incluíram zimogramas com gelatina e ensaios fluorimétricos com DQ gelatin. A solubilização do captopril reduziu significativamente o pH da solução tampão 50 mM (p<0,01) mas não alterou o pH da solução tampão 200 mM (p>0,05). Resultados de zimografia do plasma e da rhMMP-2 mostraram inibição da atividade gelatinolítica com significância estatística somente em concentrações iguais ou maiores que 4 e 1 mM de captopril, respectivamente (p<0,05). A presença de captopril nos ensaios de fluorimetria resultaram na inibição significante da atividade de rhMMP-2 somente em concentrações iguais ou maiores que 2 mM (p<0,01), enquanto a rhMMP-2 ativada com APMA apresentou inibição significativa diante de 0,5 mM de captopril (p<0,01). As concentrações de captopril efetivas em inibir a MMP-2 in vitro foram muito superiores àquelas referentes à concentração plasmática máxima encontrada no plasma humano após a administração de uma dose de 50 mg de captopril. Em conjunto nossos resultados sugerem que o captopril não parece promover inibição significativa da MMP-2 nas concentrações relatadas in vivo. Além disso, o pH das soluções tamponantes é um aspecto que requer mais atenção durante ensaios de inibição de protease in vitro. / MMP-2 is involved in many physiological and pathological processes. This protease shares structural similarities with the angiotensin-converting enzyme (ACE), and ACE inhibitors have been described to inhibit MMP-2. However, this inhibitory potential has not been tested using a highly purified MM-2 so far. This study aimed at investigating the inhibitory potential of captopril on MMP-2 activity. First it was tested whether the dissolution of captopril would induce changes in the pH of the solutions. Secondly, the direct inhibitory effect of captopril on plasma MMP-2 and on a recombinant human MMP-2 (rhMMP-2) produced and purified from E. coli was tested. The in vitro activity assays included gelatin zymography and a fluorimetric assay with DQ gelatin. Captopril solubilization significantly decreased the pH of the 50 mM Tris buffer solution (p<0.01) but did not decreased the pH of the 200 mM Tris Buffer solution (p>0.05). Zymography results of plasma and rhMMP-2 showed that inhibition of the activity only reached statistical significance >= 4 and 1 mM of captopril, respectively (p<0,05). The presence of captopril in the fluorimetric assay resulted in a significant inhibition of the rhMMP-2 activity only at concentrations >= 2 mM (p<0.01), whereas APMA-activated rhMMP-2 was inhibited by 0.5 mM of captopril (p<0.01). The captopril concentrations found to inhibit MMP-2 are several times of magnitude higher than the maximum plasma concentration after a dose of 50 mg of captopril. In conclusion, captopril does not seem to cause significant inhibition of MMP-2 in the concentrations found in vivo, and more attention has to be given to the pH of the solutions when testing protease inhibition in vitro.

A MMP-2 é uma protease que está envolvida em muitos eventos fisiológicos e patológicos e que compartilha similaridades estruturais com a enzima conversora de angiotensina (ECA), de modo que os inibidores da ECA passaram a ser estudados com relação ao efeito inibitório também sobre a MMP-2. No entanto, este potencial inibitório não foi ainda testado na MMP-2 altamente purificada. Este estudo teve como objetivo investigar o potencial inibitório do captopril sobre a atividade da MMP- 2. Primeiramente, supôs-se que a dissolução do captopril poderia induzir a mudanças no pH de soluções tampão. Em segundo lugar, avaliou-se o efeito direto do captopril sobre a MMP-2 presente no plasma humano e a MMP-2 recombinante humana (rhMMP-2) produzida e purificada de E. coli. As análises de atividade in vitro incluíram zimogramas com gelatina e ensaios fluorimétricos com DQ gelatin. A solubilização do captopril reduziu significativamente o pH da solução tampão 50 mM (p<0,01) mas não alterou o pH da solução tampão 200 mM (p>0,05). Resultados de zimografia do plasma e da rhMMP-2 mostraram inibição da atividade gelatinolítica com significância estatística somente em concentrações iguais ou maiores que 4 e 1 mM de captopril, respectivamente (p<0,05). A presença de captopril nos ensaios de fluorimetria resultaram na inibição significante da atividade de rhMMP-2 somente em concentrações iguais ou maiores que 2 mM (p<0,01), enquanto a rhMMP-2 ativada com APMA apresentou inibição significativa diante de 0,5 mM de captopril (p<0,01). As concentrações de captopril efetivas em inibir a MMP-2 in vitro foram muito superiores àquelas referentes à concentração plasmática máxima encontrada no plasma humano após a administração de uma dose de 50 mg de captopril. Em conjunto nossos resultados sugerem que o captopril não parece promover inibição significativa da MMP-2 nas concentrações relatadas in vivo. Além disso, o pH das soluções tamponantes é um aspecto que requer mais atenção durante ensaios de inibição de protease in vitro. / MMP-2 is involved in many physiological and pathological processes. This protease shares structural similarities with the angiotensin-converting enzyme (ACE), and ACE inhibitors have been described to inhibit MMP-2. However, this inhibitory potential has not been tested using a highly purified MM-2 so far. This study aimed at investigating the inhibitory potential of captopril on MMP-2 activity. First it was tested whether the dissolution of captopril would induce changes in the pH of the solutions. Secondly, the direct inhibitory effect of captopril on plasma MMP-2 and on a recombinant human MMP-2 (rhMMP-2) produced and purified from E. coli was tested. The in vitro activity assays included gelatin zymography and a fluorimetric assay with DQ gelatin. Captopril solubilization significantly decreased the pH of the 50 mM Tris buffer solution (p<0.01) but did not decreased the pH of the 200 mM Tris Buffer solution (p>0.05). Zymography results of plasma and rhMMP-2 showed that inhibition of the activity only reached statistical significance >= 4 and 1 mM of captopril, respectively (p<0,05). The presence of captopril in the fluorimetric assay resulted in a significant inhibition of the rhMMP-2 activity only at concentrations >= 2 mM (p<0.01), whereas APMA-activated rhMMP-2 was inhibited by 0.5 mM of captopril (p<0.01). The captopril concentrations found to inhibit MMP-2 are several times of magnitude higher than the maximum plasma concentration after a dose of 50 mg of captopril. In conclusion, captopril does not seem to cause significant inhibition of MMP-2 in the concentrations found in vivo, and more attention has to be given to the pH of the solutions when testing protease inhibition in vitro.

Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 164-207.